Category Archives: Business of Biotech

Long-term immune response for Vical’s TransVax™ vaccine in Phase 2 trial

Vical Incorporated (Nasdaq:VICL) announced that TransVax™ cytomegalovirus vaccine continued to demonstrate an overall increase in cellular immune responses compared with placebo at the seven-month immunogenicity data point in an ongoing Phase 2 trial.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Inovio reports clinical trial progress of cervical cancer vaccine

Inovio Biomedical Corporation (NYSE Amex: INO) announced safety and immunogenicity data from its therapeutic cervical cancer vaccine (VGX-3100) trial. VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus types 16 and 18 and is delivered via in vivo electroporation. The vaccine was found to be generally safe and well tolerated, and achieved significant cellular and humoral immune responses at the lowest dose administered. Read the release.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Immunovaccine begins trading as “IMV”

Immunovaccine Inc. (TSX-V:IMV) will begin trading on the TSX-Venture Exchange as a Tier 1 issuer under the ticker symbol “IMV”. Immunovaccine Inc. also announces the closing of the previously announced private placement totaling $8,269,109 in gross proceeds. The TSX Venture Exchange has accepted the private placement for filing.  Read the release.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Oncolytics enters into agreement with FDA for Phase 3 trial of REOLYSIN®

Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) has reached an agreement with the FDA under the Special Protocol Assessment (SPA) process for the design of a Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. The SPA is an agreement between Oncolytics and the FDA that the design and planned analyses of the Phase 3 study is adequately designed to provide the necessary data, that depending Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

WILEX receives approval for Phase I trial

WILEX AG (ISIN DE0006614720 / Frankfurt Stock Exchange / Prime Standard) announced that the German Federal Institute for Drugs and Medical Devices approved the Phase I trial with the MEK inhibitor WX-554. The trial is a first-in-man-trial in healthy volunteers and will be conducted at a single site in Germany. With the first dose in man, the second milestone payment of EUR 5 million agreed in the strategic alliance with UCB Pharma S.A. will become Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,